Blincyto
Biological
Amgen Inc.
Total Payments
$471.8M
Transactions
13,753
Doctors
5,070
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.4M | 908 | 360 |
| 2023 | $5.9M | 3,312 | 2,260 |
| 2022 | $53.2M | 2,334 | 1,439 |
| 2021 | $93.8M | 2,024 | 1,114 |
| 2020 | $81.2M | 994 | 461 |
| 2019 | $51.9M | 1,571 | 680 |
| 2018 | $87.2M | 1,615 | 645 |
| 2017 | $88.1M | 995 | 350 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $467.5M | 893 | 99.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 849 | 0.4% |
| Consulting Fee | $1.4M | 488 | 0.3% |
| Travel and Lodging | $525,956 | 1,084 | 0.1% |
| Food and Beverage | $323,678 | 10,309 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $230,029 | 119 | 0.0% |
| Royalty or License | $45,300 | 3 | 0.0% |
| Education | $814.33 | 8 | 0.0% |
Payments by Type
Research
$467.5M
893 transactions
General
$4.3M
12,860 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 103 CRADA various titles | Amgen Inc. | $247.2M | 0 |
| Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) | Amgen Inc. | $21.7M | 0 |
| Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) with Low-intensity Chemotherapy in Patients with Acute Lymphoblastic Leukemia (ALL) | Amgen Inc. | $21.1M | 0 |
| 1st Line P2 study to evaluate Blincyto in combination with R-Chemo in subjects with high risk DLB | Amgen Inc. | $15.3M | 3 |
| Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab as Frontline Therapy for Adults with B-Cell Lineage Acute Lymphocytic Leukemia | Amgen Inc. | $14.4M | 0 |
| Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal Residual Disease after Frontline Therapy | Amgen Inc. | $13.1M | 0 |
| P1b/2 SC Dose Esc & Exp R/R & MRD ALL | Amgen Inc. | $12.4M | 0 |
| TOTAL THERAPY STUDY XVII (TOTXVII) FOR NEWLY DIAGNOSED PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOM | Amgen Inc. | $10.8M | 0 |
| A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults | Amgen Inc. | $10.2M | 0 |
| Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab with or without Inotuzumab Ozogamicin as Frontline Therapy for Adults with B-Cell Lineage Acute Lymphocytic Leukemia | Amgen Inc. | $9.7M | 0 |
| Blinatumomab for relapsed or refractory indolent Non-Hodgkin lymphoma | Amgen Inc. | $9.2M | 0 |
| CRADA: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL | Amgen Inc. | $8.8M | 0 |
| A phase II study of blinatumomab in Richter's Transformation | Amgen Inc. | $7.9M | 0 |
| Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia | Amgen Inc. | $6.4M | 0 |
| Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 100135, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) | Amgen Inc. | $6.4M | 0 |
| Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients with Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) | Amgen Inc. | $5.3M | 0 |
| A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with | Amgen Inc. | $4.8M | 3 |
| A Phase I/II study of blinatumomab in combination with pembrolizumab (MK-3475) for adults with relapsed or refractory B-lineage acute lymphoblastic leukemia with high bone marrow lymphoblast percentage | Amgen Inc. | $3.5M | 0 |
| A phase IB/II study of blinatumomab in patients with pre B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHL) as post-allogeneic stem cell transplant (allo-HSCT) remission maintenance | Amgen Inc. | $3.0M | 0 |
| Phase 1b SubQ study | Amgen Inc. | $2.7M | 0 |
Top Doctors Receiving Payments for Blincyto
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $467.8M | 969 |
| , M.D | Hematology | New York, NY | $310,733 | 336 |
| , M.D | Hematology & Oncology | Houston, TX | $228,792 | 120 |
| , M.D | Hematology | Hackensack, NJ | $132,573 | 127 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $128,775 | 121 |
| , M.D | Specialist | Atlanta, GA | $122,474 | 138 |
| , M.D | Hematology | Washington, DC | $115,056 | 141 |
| , MD, PHD | Internal Medicine | San Francisco, CA | $114,536 | 104 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $110,173 | 113 |
| , MD | Internal Medicine | Duarte, CA | $99,787 | 89 |
| , MD | Medical Oncology | Houston, TX | $88,174 | 39 |
| , MD | Internal Medicine | New York, NY | $86,920 | 51 |
| , MD | Internal Medicine | New York, NY | $82,179 | 82 |
| , NP | Nurse Practitioner | Palo Alto, CA | $77,097 | 184 |
| , M.D | Pediatric Hematology-Oncology | Milwaukee, WI | $76,057 | 85 |
| , MD | Hematology & Oncology | Charleston, SC | $63,661 | 62 |
| , MD | Internal Medicine | Orlando, FL | $59,415 | 56 |
| , MD | Pediatric Hematology-Oncology | Memphis, TN | $58,659 | 19 |
| , MD | Hematology | Philadelphia, PA | $58,465 | 27 |
| , MD | Internal Medicine | San Juan, PR | $55,306 | 67 |
| , M.D, PH.D | Internal Medicine | Orlando, FL | $51,945 | 70 |
| , M.D | Internal Medicine | Seattle, WA | $46,554 | 25 |
| , M.D | Internal Medicine | Omaha, NE | $44,846 | 48 |
| , MD | Medical Oncology | Seattle, WA | $42,874 | 36 |
| , MD | Hematology & Oncology | Houston, TX | $42,728 | 11 |
Ad
Manufacturing Companies
- Amgen Inc. $471.8M
Product Information
- Type Biological
- Total Payments $471.8M
- Total Doctors 5,070
- Transactions 13,753
About Blincyto
Blincyto is a biological associated with $471.8M in payments to 5,070 healthcare providers, recorded across 13,753 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $10.4M was paid across 908 transactions to 360 doctors.
The most common payment nature for Blincyto is "Unspecified" ($467.5M, 99.1% of total).
Blincyto is associated with 20 research studies, including "103 CRADA various titles" ($247.2M).